ESKD

New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment

Retrieved on: 
Friday, November 10, 2023
Research, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, OAC, International Society, Safety, ESKD, Executive Committee, Risk, Thrombosis, Patient, Atrial fibrillation, Stroke, Bleeding, Trial of the century, Kidney disease, Physician, Pharmaceutical industry, Birth control, ISTH, Hemostasis, Medicine, Bayer

Bayer today announced it expanded its Phase III OCEANIC clinical development program for the investigational drug asundexian (BAY2433334) by initiating a third clinical study, OCEANIC-AFINA.

Key Points: 
  • Bayer today announced it expanded its Phase III OCEANIC clinical development program for the investigational drug asundexian (BAY2433334) by initiating a third clinical study, OCEANIC-AFINA.
  • OCEANIC AFINA is a Phase III study investigating asundexian as a potential treatment option in patients (≥65 years of age) with atrial fibrillation (AF) at high risk for stroke or systemic embolism who are deemed ineligible for oral anticoagulation (OAC) treatment due to an increased risk of bleeding.
  • OCEANIC-AFINA complements OCEANIC-AF, an ongoing Phase III study investigating the efficacy and safety of asundexian for the prevention of stroke or systemic embolism in people with AF.
  • “It is our vision to support patients with atrial fibrillation, including those, that up to now were deemed as not eligible for treatment with OACs.

Kidneylink Announces Program Growth in Value-Based Kidney Care

Retrieved on: 
Wednesday, December 13, 2023
NPS, Chronic kidney disease, Kidney disease, Associate, ESKD, Pharmacist, Risk, RNS, Patient, Nephrology, USRC, Dialysis, CKD, Kidney transplantation, MD, Partnership, Social, Growth, Physician, FASN, Quality of life, Hospital, HIV disease progression rates, Pharmaceutical industry, Nursing

PLANO, Texas, Dec. 13, 2023 /PRNewswire/ -- Kidneylink – a national, value-based kidney care company founded by U.S. Renal Care, is pleased to announce significant growth and success on behalf of its patients and providers – expanding its network to more than 600 nephrologists across 20 U.S. based markets and caring for more than 16,000 people living with kidney disease, both Chronic Kidney Disease (CKD) and End Stage Kidney Disease (ESKD). Since its inception in 2021, Kidneylink has improved clinical outcomes for patients resulting in double-digit percentage reductions in hospitalizations and medical costs.

Key Points: 
  • PLANO, Texas, Dec. 13, 2023 /PRNewswire/ -- Kidneylink – a national, value-based kidney care company founded by U.S. Renal Care , is pleased to announce significant growth and success on behalf of its patients and providers – expanding its network to more than 600 nephrologists across 20 U.S. based markets and caring for more than 16,000 people living with kidney disease, both Chronic Kidney Disease (CKD) and End Stage Kidney Disease (ESKD).
  • Kidneylink is also not limited to U.S. Renal Care dialysis centers—more than 50% of Kidneylink ESKD patients are treated outside of USRC's facilities.
  • Many value-based kidney organizations rely on virtual care management teams that work around the nephrologist.
  • The future of kidney care is value-based care.

Alio Officially Enters GCC Market Through Partnership with Al Redwan

Retrieved on: 
Tuesday, December 5, 2023
Calibration, Vascular occlusion, Chronic kidney disease, ESKD, Potassium, Kidney disease, Patient, Dialysis, Kidney, FDA, Hematocrit, Auscultation, Blood, Partnership, Death, Hospital, Quality of life, Health, Alió, Kingdom

BROOMFIELD, Colo., Dec. 5, 2023 /PRNewswire/ -- Today, Alio, Inc. announces its strategic partnership with Al Redwan Medical Services Company, a leader in dialysis and medical lab trading and medical services in the Gulf region. Alio, already commercially available in the United States, has expanded its global presence to the Kingdom of Saudi Arabia to reach a greater number of kidney patients in need.

Key Points: 
  • The Alio Platform dramatically improves the technology solutions available to clinicians by delivering actionable, clinical-grade metrics and notifications at key intervention points.
  • Alio's partnership with Al Redwan allows Alio to manage the more than 3,000 End-Stage Kidney Disease (ESKD) patients for whom Al Redwan directly provides dialysis.
  • Beyond the patients already under Al Redwan's care, the partnership will also enable and facilitate the distribution of Alio products to other hospitals, providers, and partners in the region, including Diaverum.
  • Unfortunately, the technology available to date has only catered to one or two of their conditions," said Mr. Yousef Al Redwan, CEO of Al Redwan Medical Services.

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, November 7, 2023
Generalized arterial calcification of infancy, Patient, Research, Research and development, Genomics, Clinical trial, PD, Calciphylaxis, Therapy, Biomarker, ESKD, G&A, American Society of Nephrology, Conference, Pros, Kidney disease, R, American Society for Bone and Mineral Research, Society, PXE, Columbia University School of General Studies, ENPP1, ASN, PK, Clinical Global Impression, Annual general meeting, GIC, Safety, ABCC6, Investment, Doctor of Philosophy, Administration, Nursing, Pharmaceutical industry

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.

Key Points: 
  • Patient recruitment is underway, and the Company remains on track to report topline data in mid-2025.
  • Exploratory efficacy data reported suggested clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient-reported outcomes (PROs), and functional outcomes.
  • R&D Expenses were $13.3 million for the quarter ended September 30, 2023, compared to $12.2 million for the prior-year period.
  • Net loss was $16.6 million, or $0.29 loss per share, for the quarter ended September 30, 2023, compared to $16.4 million, or $0.38 loss per share, for the prior-year period.

Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, October 26, 2023
Patient, FDA, ECTS, IND, Pyrophosphate, Incidence, Food, Therapy, ESKD, Mortality, Skin, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, American Society of Nephrology, Plasma, Disorder, Clinical trial, ASN, Kidney disease, Blood, Death, Infection, Pharmaceutical industry, Calciphylaxis

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held November 2-5, 2023 in Philadelphia, PA.

Key Points: 
  • BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held November 2-5, 2023 in Philadelphia, PA.
  • Details of the presentation are as follows:
    Title: Role of Plasma Inorganic Pyrophosphate in Calciphylaxis: A Prospective Study
    Calciphylaxis is a rare disorder with a high mortality rate that mostly affects patients with end stage kidney disease (ESKD).
  • The estimated incidence of calciphylaxis is at least 1,800 new patients per year in the United States and there are no approved therapies.
  • Inozyme previously presented data at the European Calcified Tissue Society Congress (ECTS) which showed that morbidity and mortality in patients with calciphylaxis were associated with low levels of PPi.

DaVita Collaborates with Google Cloud to Develop Customized Clinical Operating System Designed to Transform Kidney Care

Retrieved on: 
Wednesday, October 18, 2023
Cloud, Medical Affairs Bureau, NYSE, BigQuery, Crash, ESKD, Kidney failure, National Kidney Foundation, Organization, Kidney disease, Google Cloud, Chronic kidney disease, DaVita Inc., Dialysis, Caregiver, IA Financial Group, Machine learning, Hospital, CKD, AI, Google Cloud Platform, Patient, Society for Healthcare Strategy and Market Development, Medical device, Pharmaceutical industry, Nursing

SUNNYVALE, Calif., Oct. 18, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) and Google Cloud today announced that the organizations have collaborated to create a new clinical operating system that sets a foundation for streamlined kidney care for more than 200,000 DaVita patients.

Key Points: 
  • Kidney care provider harnesses the power of Google Cloud's leading-edge infrastructure, AI, and analytics tools to help improve care plans and streamline clinical workflows
    SUNNYVALE, Calif., Oct. 18, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) and Google Cloud today announced that the organizations have collaborated to create a new clinical operating system that sets a foundation for streamlined kidney care for more than 200,000 DaVita patients.
  • With the deployment, DaVita has moved from a decentralized clinical documentation system to a unified platform that leverages data from more than 30 million dialysis treatments per year to generate insights designed to help improve clinical outcomes.
  • Ultimately, the platform is designed to support DaVita's mission to provide integrated kidney care that helps, improve patient quality of life, and lower the cost of care.
  • A leader in kidney care, DaVita has more than 20 years of clinical data, based on the more than 30 million dialysis treatments the organization administers each year.

Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023

Retrieved on: 
Wednesday, October 18, 2023
Patient, Burden, PDUFA, Food, Booth, ESKD, EST, AKBA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Poster, Society, Abstract (summary), Chronic kidney disease, Convention, National Primate Research Exhibition Hall, New Drug Application, Kidney disease, Anemia, Kidney, Pennsylvania Convention Center, Pharmaceutical industry, Akebia, Hyperphosphatemia, Dialysis

CAMBRIDGE, Mass., Oct. 18, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2023 (ASN Kidney Week), which will take place at the Pennsylvania Convention Center in Philadelphia from November 2-5, 2023.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 18, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2023 (ASN Kidney Week), which will take place at the Pennsylvania Convention Center in Philadelphia from November 2-5, 2023.
  • Akebia-supported posters will be presented at ASN Kidney Week on November 2, 2023, from 10:00 a.m. – 12:00 p.m. EST.
  • ASN Kidney Week attendees can also visit Akebia at Booth #2515 in the Exhibit Hall.
  • Notably, Akebia will present a poster with data on alternate dosing for vadadustat, its investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.

Monogram Health Welcomes Adam McAnaney to Executive Leadership Team

Retrieved on: 
Tuesday, October 17, 2023
Investment, McAnaney, Columbia Law School, Acquisition, Corporation, General counsel, Disclosure, CKD, Oliver Cromwell, ESKD, JD, Health, Aetna, Sullivan & Cromwell, BA, Entrepreneurship, History, Kidney disease, Yale University, Patient, Monogram, Management

NASHVILLE, Tenn., Oct. 17, 2023 /PRNewswire/ -- Monogram Health , the nation's leading value-based provider of in-home, evidence-based care and benefit management services for patients living with chronic kidney and end stage kidney disease, has hired Adam McAnaney as Chief Legal Officer and Secretary.

Key Points: 
  • NASHVILLE, Tenn., Oct. 17, 2023 /PRNewswire/ -- Monogram Health , the nation's leading value-based provider of in-home, evidence-based care and benefit management services for patients living with chronic kidney and end stage kidney disease, has hired Adam McAnaney as Chief Legal Officer and Secretary.
  • Adam is a proven leader, and his extensive history of successful executive leadership roles at public companies as well as large-scale healthcare organizations demonstrates his robust capabilities.
  • "Adam has a clear and expert understanding of the unique needs among our patients, clinicians, investors and health plan partners, and will drive great value for Monogram Health as we continue to expand our proven in-home care delivery model across the U.S.," said Monogram Health CEO and Co-Founder Mike Uchrin.
  • Adam served as General Counsel and Secretary for Signify Health, following its acquisition of Remedy Partners.

Maze Therapeutics Announces Publication of Research Demonstrating Newly Identified Variant for APOL1 Kidney Disease is Associated with Reduced Risk of APOL1 Kidney Disease

Retrieved on: 
Wednesday, October 11, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Journal of the American Society of Nephrology, HIV disease progression rates, CKD, Risk, APOL1, Society, Toxicity, ESKD, Vanderbilt University Medical Center, Apolipoprotein L1, Kidney, Disease, JASN, Patient, Therapy, Noetics, Journal, Chronic kidney disease, CDK, Kidney disease, Bangladesh Technical Education Board, Human, Acute kidney injury, Pharmaceutical industry, Maze

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the publication of research validating the protective role and mechanism of an APOL1 genetic variant– p.N264K— in chronic kidney disease (CDK) and end stage kidney disease (ESKD) among carriers with high-risk variants.

Key Points: 
  • Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the publication of research validating the protective role and mechanism of an APOL1 genetic variant– p.N264K— in chronic kidney disease (CDK) and end stage kidney disease (ESKD) among carriers with high-risk variants.
  • Apolipoprotein L1 (APOL1) is a protein encoded by the APOL1 gene in humans.
  • Genetic variants of the gene (G1 and G2) are associated with increased risk for a spectrum of progressive kidney diseases in people of African ancestry.
  • Variant functionalization studies in cell models were also conducted, which showed that APOL1 p.N264K blocked APOL1 pore-forming function and ion conductance and reduced toxicity of APOL1 high-risk mutations.

Alio's Remote Monitoring Platform Now Notifies Clinicians of Atypical Acoustic Data from Patients with Vascular Access

Retrieved on: 
Thursday, September 28, 2023
Auscultation, Infection, Partnership, Hospital, Stenosis, Hematocrit, The Rev, Research, Elective surgery, Lifeline, Dialysis, Sepsis, Friction, Patent, Patient, Risk, Medicine, Heart rate, ESKD, Health, FDA, Skin temperature, Potassium, Death, Fistula, Medical device, Medical imaging, Alió, Duplex

BROOMFIELD, Colo., Sept. 28, 2023 /PRNewswire/ -- Today, Alio, Inc. announces the release of a new feature for its remote monitoring platform which notifies clinical care teams when there is a gap in typical acoustic data from a patient's vascular access site. While the platform was FDA-cleared in March of this year to function as a stethoscope and collect auscultation data, this new notification draws the clinician's attention to a specific set of recordings which indicate the absence of typical sound data. The standard approach to monitoring a patient's vascular access has required in-person manual readings with a stethoscope. Rather than manually taking readings, the Alio SmartPatch automatically takes readings and makes it possible for clinicians to monitor a patient's vascular access remotely with no action required from the patient. 

Key Points: 
  • BROOMFIELD, Colo., Sept. 28, 2023 /PRNewswire/ -- Today, Alio, Inc. announces the release of a new feature for its remote monitoring platform which notifies clinical care teams when there is a gap in typical acoustic data from a patient's vascular access site.
  • The standard approach to monitoring a patient's vascular access has required in-person manual readings with a stethoscope.
  • Sound data from the vascular access is essential in managing an ESKD patient's condition and preserving a critical lifeline.
  • The Alio Remote Monitoring Platform makes it possible for clinicians to receive timely notifications regarding their patients.